The New England Journal of Medicine A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy A Research Summary based on Lafayette R et al. | 10.1056/NEJMoa2510198 | Published on November 6, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. Full ORIGIN 3 trial results and Research Summary: nej.md/3JEq8QL
#MedSky